In a challenging year for Aclarion, the medical technology company's stock has plummeted to a 52-week low, trading at $4.41. According to InvestingPro data, the company maintains a healthy liquidity ...

Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...

Northwestern Medicine is a global leader in clinical trial research, including spineCLARITY is a randomized study designed to demonstrate ...

Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE ...

Aclarion stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its ...

Aclarion is recognized for leveraging MRS technology to improve the diagnosis of chronic low back pain through its Nociscan platform, which assists physicians in distinguishing between painful and ...

Participants and those ... Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer ...

Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...

The trial aims to validate Nociscan's ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data ...

CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in ...

The trial aims to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data ...